티바디 테라퓨틱스(TVRD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.90 (+7.34%), 시가총액 $0.04B, 52주 범위 $2.85 ~ $42.98.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in
티바디 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
티바디 테라퓨틱스의 현재 주가는 $1.90 (+7.34%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
티바디 테라퓨틱스의 시가총액은 약 $0.04B입니다.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcriptio